We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,170.00
Bid: 12,166.00
Ask: 12,170.00
Change: 0.00 (0.00%)
Spread: 4.00 (0.033%)
Open: 12,114.00
High: 12,258.00
Low: 12,114.00
Prev. Close: 12,170.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks buoyed by Covid studies and treatments

Thu, 23rd Dec 2021 12:20

(Alliance News) - Stock prices in London were higher at midday on Thursday on optimism over the weaker severity of the Omicron variant of Covid-19, supported by scientific studies, booster shots and oral antiviral treatments.

In separate studies, scientists in South Africa, London and Scotland found that catching Omicron is less likely to result in severe symptoms and hospital admission than earlier Covid strains such as Delta.

These studies have strengthened hopes that Omicron is unlikely to curtail the global economic recovery.

In addition, AstraZeneca announced data from a new laboratory study showing that a third dose of Vaxzevria, its Covid-19 vaccine, significantly boosted levels of antibodies against the Omicron variant.

In the study, the Anglo-Swedish drugmaker said that neutralisation titres for Omicron were raised following a third dose with Vaxzevria, compared to titres after a second dose. In addition, the levels after the third dose booster were higher than the neutralising antibodies found in those previously infected with and recovered naturally from the prior variants.

Shares in AstraZeneca were 0.1% lower in London at midday.

The FTSE 100 index was up 12.29 points, or 0.2%, at 7,353.85. The mid-cap FTSE 250 index was up 171.45 points, or 0.7%, at 23,252.24. The AIM All-Share index was up 5.80 points, or 0.5% at 1,189.61.

The Cboe UK 100 index was up 0.4% at 729.80. The Cboe 250 was 0.9% higher at 20,663.64. The Cboe Small Companies was up 0.5% at 15,080.22.

In mainland Europe, the CAC 40 stock index in Paris was up 0.5%, while the DAX 40 in Frankfurt was 0.3% higher.

Analysts at OFX said: "Investors struck a more positive sentiment in the financial markets, as three separate reports suggested that the Omicron variant may result in less severe illness than previous variants of the virus.

"The old theory of the 'Santa rally' seems to also hold true this year as the markets rise ahead of Christmas. Whether this lasts post the Christmas euphoria appears to be seen, as there is a bumpy road ahead with much uncertainty around Covid and its variants, China's Evergrande story and inflationary pressures in 2022."

In the FTSE 100, travel and leisure stocks were among the best performers.

British Airways-parent International Consolidated Airlines was the best performer, up 3.5%. Budget carriers easyJet and Wizz Air were among the biggest midcap gainers, up 4.2% and 3.2%, respectively. AIM-listed Jet2 was up 4.6%.

Blue-chip hotel operators Whitbread and InterContinental Hotels Group were up 2.4% and 1.7% respectively.

Flutter Entertainment was up 2.7%. The gambling firm bought Milan-based online gaming operator Sisal from CVC Capital Partners Fund for EUR1.91 billion, in a bid to attain "a gold medal position" in the Italian market.

Dublin-based Flutter, formerly known as Paddy Power Betfair, said the transaction is likely to complete during the second quarter of 2022 and is expected to be accretive to adjusted earnings in the first 12 months after completion.

Flutter said the deal increases its exposure to an "attractive, fast-growing, regulated online market". The company highlighted that Italy is Europe's second largest regulated gambling market and one that has seen online penetration grow from 10% in 2019 to 20% in 2021.

At the other end of the large-caps, Evraz and British American Tobacco were the worst performers, down 3.3% and 2.7%, respectively. The stocks went ex-dividend, meaning new buyers no longer qualify for the latest payout.

In the FTSE 250, Balfour Beatty was up 2.5% after the construction firm said its US subsidiary Balfour Beatty Communities has reached a resolution with the Department of Justice.

Balfour Beatty said the deal resolves the DoJ's criminal and civil investigations into some performance incentive fees improperly claimed by Communities between 2013 and 2019, related to maintenance work at US military housing installations.

Under the terms of the resolution, Communities has pleaded guilty to one count of fraud and has agreed to the appointment of an independent compliance monitor for a three-year period. Communities cooperated fully with the DoJ in its investigation, Balfour said.

Communities will pay a total resolution amount of USD65.4 million, comprised of USD33.6 million in penalties and USD31.8 million in restitution, Balfour added.

At the other end of the midcaps, Reach was the worst performer, down 3.5%. The Telegraph reported late Wednesday the newspaper publisher faces intervention by the UK Pensions Regulator for not increasing contributions to address a large funding deficit.

The trustee of its pension fund, in a letter to scheme members last week, said it had "requested that the Pension Regulator now take a more active role to try to help reach a positive outcome for all stakeholders", according to the Telegraph.

"Any solution to this will need to involve additional contributions, which in the trustee's view are readily affordable by the company in the period to 2027," a spokesperson for the trustee said.

In response, Reach told the Telegraph: "The company and the board remain committed to working towards the objective of achieving funding of all schemes as previously agreed in our 2016 review."

On AIM, Libertine Holdings made its stock market debut trading at 30 pence, up 50% from its initial public offering price of 20p. The Sheffield, England-based company offers technology for power generation from renewable fuels, making linear electrical machines for original equipment manufacturers of powertrains.

The pound was quoted at USD1.3420 at midday Thursday, up from USD1.3346 at the London equities close Wednesday.

The euro was priced at USD1.1328, unmoved from USD1.1327. Against the yen, the dollar was trading at JPY114.30, marginally higher from JPY114.22.

Brent oil was quoted at USD75.40 a barrel Thursday at midday, up sharply from USD74.74 a barrel at the London equities close Wednesday. Gold stood at USD1,805.56 an ounce, higher against USD1,797.90.

US stock index futures were pointed to a higher open amid cautious optimism after the US Food & Drug Administration on Wednesday authorised Pfizer's oral Covid-19 treatment. Shares in the New York-based drugmaker were up 0.5% in pre-market trade.

The Dow Jones Industrial Average was called up 0.3%, the S&P 500 up 0.3%, and the Nasdaq Composite up 0.2%.

Paxlovid, which comprises two types of tablet, was granted an emergency use authorization by the FDA after a clinical trial showed it to reduce the risk of hospitalisations and deaths among at-risk people by 88%.

Thursday's economic calendar has US initial jobless claims at 1330 GMT, alongside durable goods orders and personal consumption expenditures due at the same time.

Financial markets in the US will be closed on Friday in observance of Christmas, while the London Stock Exchange will close at 1230 GMT. New York will reopen on Monday, but London will remain closed until Wednesday.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
Today 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
Today 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.